Citigroup analyst John Deakin-Bell upgrades ResMed (NYSE:RMD) from Neutral to Buy.
Where Regeneron Pharmaceuticals Stands With Analysts
Over the past 3 months, 10 analysts have published their opinion on Regeneron Pharmaceuticals (NASDAQ:REGN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
